Aptus Pharma IPO

About Aptus Pharma IPO

Aptus Pharma Limited is launching its IPO in September 2025, with a fresh issue size of 18,60,000 equity shares of face value of ₹10 each, aggregating up to an undisclosed amount. The IPO price band is TBA. The lot size is TBA.

The IPO opening date is September 23, 2025 and the closing date is September 25, 2025. The allotment date is September 26, 2025. The tentative listing date is September 30, 2025. The credit of shares to the demat account will take place on September 29, 2025.

Objectives of Aptus Pharma IPO

• Capital expenditure for office premises with furniture and industrial racks.
  
• Working capital.
  
• General corporate purposes.
  

Industry Outlook

The Indian pharmaceutical industry outlook remains strong, backed by the country’s robust economic growth and supportive government policies. Nominal GDP for FY25 is projected at ₹33.10 lakh crore (US$3.8 trillion), growing at 9.9% compared to FY24. Exports play a major role, with India’s exports for FY25 standing at ₹37.31 lakh crore (US$433.56 billion), including key categories such as engineering goods (26.88%), petroleum products (13.86%), and electronic goods (8.89%). Real GDP growth for 2023–24 is estimated at 8.2%, higher than 7.0% in 2022–23, reflecting resilience. With India ranked 5th in global FDI inflows, the pharma sector is expected to benefit from rising capital expenditure, estimated at ₹47.65 lakh crore (US$571.64 billion) in 2024–25.

Company Information

Aptus Pharma Limited was incorporated on August 12, 2010, as a private company and later converted into a public limited company on December 12, 2024. The company is engaged in the marketing and distribution of finished pharmaceutical formulations. It operates on a contract manufacturing model, having agreements with seven manufacturing units, including formal loan and license arrangements with two of them. Aptus Pharma offers a wide portfolio of products across therapeutic categories like anti-infectives, gastrointestinal, cardiovascular, anti-diabetic, and wellness supplements. Its products come in various dosage forms such as tablets, syrups, injections, ointments, capsules, and gels.

Strengths of Aptus Pharma IPO

• Diversified product portfolio
  
• Robust and responsive distribution network
  
• Strategic manufacturing alliance
  
• Commitment to high-quality standards
  
• Competitive and cost-effective pricing
  
• Skilled and committed human resources
  
• Experienced and visionary management team
  
• Customer satisfaction and retention
  

Risks of Aptus Pharma IPO

• The company does not own manufacturing facilities and relies on third parties for contract manufacturing, creating dependency risks.
  
• Any decline in product quality or delays by contract manufacturers could harm reputation and sales.
  
• The business is subject to extensive government regulations; failure to comply may result in penalties, operational restrictions, or reputational harm.
  
• A significant portion of revenue comes from a few customers; loss or reduced orders from them could materially impact financial performance.
  
• Inability to protect intellectual property rights could harm operations, profitability, and competitive position.
  
• Exposure to product liability and risks from defective medicines manufactured by third-party contractors.
  
• The business depends heavily on medical professionals for prescriptions and recommendations; changes in their preferences or practices could affect demand.
  

IPO Registrar and Book Running Lead Manager
IPO Registrar: Bigshare services private limited
Book Running Lead Manager: Interactive Financial Services Limited

Business Model

Aptus Pharma Limited follows an asset-light business model, relying on third-party contract manufacturers located in Gujarat, Himachal Pradesh, and Uttarakhand, with loan and license agreements in place with two units. These partners are WHO-GMP certified and undergo periodic audits for compliance, quality, and delivery standards.

The company maintains centrally located warehouses in Ahmedabad, spanning over 17,700 sq. ft., with a rolling stock of six months to ensure uninterrupted supply and efficient inventory control. Logistics partners handle distribution by road and air. Strong quality assurance, real-time lab analysis, and ISO and GMP certifications strengthen its operational efficiency and product reliability.

Company Growth Trajectory

Revenue from operations grew consistently from ₹13.89 crores in FY23 to ₹17.85 crores in FY24 and further to ₹24.55 crores in FY25, showing strong top-line growth. EBITDA also rose sharply from ₹0.57 crores in FY23 to ₹1.49 crores in FY24 and ₹4.75 crores in FY25, with margins improving significantly from 4.13% to 8.35% and then 19.31% over the same period.

How to Check Allotment Status of Aptus Pharma Limited IPO?

1. Visit the Registrar's Website

To check the IPO allotment status for Aptus Pharma Limited IPO, visit the official website of Bigshare Services Private Limited, the registrar for this IPO. On their IPO allotment status page, enter your Permanent Account Number (PAN), application number, or Demat account ID. Then, click the 'Submit' button to view your allotment status. Ensure you have the necessary details ready for a quick and accurate check.

2. Check on the Bombay Stock Exchange Website

The Bombay Stock Exchange (BSE) also has an IPO allotment status page. Go to www.bseindia.com and find the 'Investors' tab. Under 'Investors', click on 'IPO'. This will take you to the IPO allotment status page.

• On the BSE IPO page, follow these steps
  
• Select 'Equity' from the dropdown menu
  
• Choose ‘Aptus Pharma Limited’ in the next dropdown
  
• Enter your application number
  
• Enter your PAN
  
• Click 'Search'
  

Your Aptus Pharma Limited IPO allotment status will be displayed.

3. Verify on the National Stock Exchange Website

The National Stock Exchange (NSE) has an IPO Bid Verification module. Use this to check Aptus Pharma Limited IPO allotment status.

Go to www.nseindia.com and find the 'Invest' tab. Click on 'Verify IPO Bids' under 'Resources & Tools'.

On the NSE IPO Bid Verification page, enter:

• Application number
  
• PAN
  

Then click 'Submit'. Your Aptus Pharma Limited IPO bid, and allotment details will be displayed.

How to Apply for Aptus Pharma Limited IPO?

• Step 1: Log in to your Kotak Neo Demat account - Log in to your Demat account to access IPO investments. Next, select the current IPO section.
  

• Step 2: Specify IPO details - Enter the number of lots and the price you wish to apply for.
  

• Step 3: Enter UPI ID - After entering your UPI ID, click submit. This will place your bid with the exchange.
  

• Step 4: Mandate Notification - Your UPI app will receive a mandate notification to block funds.
  

• Step 5: Approve Request - Your funds will be blocked once you approve the mandate request on your UPI.